We are live on ! Find out more
HRTX icon

Heron Therapeutics
HRTX

186 hedge funds and large institutions have $621M invested in Heron Therapeutics in 2022 Q1 according to their latest regulatory filings, with 22 funds opening new positions, 75 increasing their positions, 47 reducing their positions, and 36 closing their positions.

New
Increased
Maintained
Reduced
Closed

202% more call options, than puts

Call options by funds: $7.75M | Put options by funds: $2.57M

60% more repeat investments, than reductions

Existing positions increased: 75 | Existing positions reduced: 47

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

7% less funds holding

Funds holding: 200 → 186 (-14)

9.13% less ownership

Funds ownership: 115.41% → 106.28% (-9.1%)

39% less first-time investments, than exits

New positions opened: 22 | Existing positions closed: 36

42% less capital invested

Capital invested by funds: $1.07B → $621M (-$453M)

Holders
186
Holders Change
-14
Holders Change %
-7%
% of All Funds
2.93%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
22
Increased
75
Reduced
47
Closed
36
Calls
$7.75M
Puts
$2.57M
Net Calls
+$5.18M
Net Calls Change
+$3.05M

Top Buyers

Rank Fund Capital Flow
1
State Street
State Street
Massachusetts
+$38.3M
2
Bank of America
Bank of America
North Carolina
+$9.23M
3
Morgan Stanley
Morgan Stanley
New York
+$8.62M
4
D.E. Shaw & Co
D.E. Shaw & Co
New York
+$5M
5
OCM
Orchard Capital Management
Illinois
+$4.4M

Top Sellers

Rank Fund Capital Flow
1
UOC
UBS O'Connor
Illinois
-$75.6M
2
TCM
Tang Capital Management
California
-$29.7M
3
SI
Sofinnova Investments
California
-$21.4M
4
RCAMU
Rothschild & Co Asset Management US
Connecticut
-$12.6M
5
Citadel Advisors
Citadel Advisors
Florida
-$10.8M
Name Holding Trade Value Shares
Change 		Change in
Stake
Carson Wealth (CWM LLC)
151
Carson Wealth (CWM LLC)
Nebraska
$11K +$11.2K +1,530 +340%
BEI
152
Benjamin Edwards Inc
Missouri
$9K +$9.18K +1,254 +520%
CA
153
Clearstead Advisors
Ohio
$8K – – –
CFGS
154
Concourse Financial Group Securities
Alabama
$8K – – –
SPIA
155
Steward Partners Investment Advisory
New York
$6K – – –
WAS
156
Winch Advisory Services
Wisconsin
$6K – – –
Northwestern Mutual Wealth Management
157
Northwestern Mutual Wealth Management
Wisconsin
$6K +$59 +8 +0.8%
CAPTRUST Financial Advisors
158
CAPTRUST Financial Advisors
North Carolina
$6K +$4.13K +564 +108%
LWP
159
Lumature Wealth Partners
Georgia
$5K – – –
KT
160
Kevin Tang
$4K – – –
DFCM
161
Dark Forest Capital Management
Puerto Rico
$4K +$2.8K +383 +106%
TWA
162
TCI Wealth Advisors
Arizona
$4K +$5.45K +745 New
MIFH
163
Migdal Insurance & Financial Holdings
Israel
$3K -$12.5K -1,711 -77%
National Bank of Canada
164
National Bank of Canada
Quebec, Canada
$3K – – –
SOW
165
State of Wyoming
Wyoming
$3K +$644 +88 +20%
APC
166
Aspire Private Capital
North Carolina
$2K – – –
Baillie Gifford & Co
167
Baillie Gifford & Co
United Kingdom
$2K – – –
COCM
168
Charter Oak Capital Management
New Hampshire
$2K – – –
EWM
169
Endurance Wealth Management
Rhode Island
$2K – – –
HNB
170
Huntington National Bank
Ohio
$2K – – –
WTA
171
Washington Trust Advisors
Massachusetts
$2K – – –
S
172
SignatureFD
Georgia
$2K +$2.58K +353 New
BHWM
173
Beaird Harris Wealth Management
Texas
$1K – – –
EWM
174
Evermay Wealth Management
Virginia
$1K – – –
First Manhattan
175
First Manhattan
New York
$1K – – –
5 6
7
8 9

HRTX Hedge Fund Activity: Q1 2022 in Review

186 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Heron Therapeutics (HRTX) for Q1 2022, worth a combined $621M — down 42% from $1.07B a quarter earlier.

Sellers outnumbered buyers: 36 funds closed out of HRTX and 22 opened new positions — a net loss of 14 holders — while 47 trimmed existing stakes and 75 added.

The largest buyer was State Street, adding an estimated $38.3M. The largest seller was UBS O'Connor, exiting entirely with an estimated $75.6M sold.

  • 186 institutional investors held Heron Therapeutics (HRTX) as of Q1 2022, down from 200 in Q4 2021.
  • Funds reported $621M of Heron Therapeutics stock for Q1 2022, down 42% quarter-over-quarter.
  • 22 funds opened new Heron Therapeutics positions in Q1 2022 and 36 closed out, a net change of -14 holders.
  • The largest Heron Therapeutics buyer in Q1 2022 was State Street, an estimated $38.3M added.
  • The largest Heron Therapeutics seller in Q1 2022 was UBS O'Connor, an estimated $75.6M sold.

Based on aggregated 13F filings for Q1 2022.